Non-profit product development partnership Aeras has announced the start of a Phase I clinical trial of a new candidate tuberculosis vaccine, designed specifically to protect against the latent form of the disease.

The clinical trial is the first to test the vaccine in humans following pre-clinical studies in latently infected animals.

The vaccine is being developed by Aeras and Statens Serum Institut (SSI)

In pre-clinical trials the vaccine demonstrated no safety concerns, and was also shown to control clinical disease and reactivation in a non-human primate model.

The trial will involve 25 adults, both with and without latent tuberculosis, and will be conducted by the South African Tuberculosis Vaccine Initiative (SATVI) at its field site in Worcester, Western Cape, South Africa.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

SSI vice-president of vaccine R&D Professor Peter Andersen said: "The advancement of this candidate from an idea to the clinic working in collaboration first with the Grand Challenges consortium and now with Aeras and SATVI is an important and exciting milestone for all the researchers involved."

Preliminary results of the trial are expected at the end of 2012.